April 2021

Using in vitro autoradiography, mu receptor binding in rat brain was characterized at different amygdala kindling stages and in amygdaloid kindled animals pretreated chronically with naloxone. Male Sprague-Dawley rats implanted with bipolar electrodes in the right amygdala received one of the following pretreatments s.c. for 14 days via osmotic minipumps: Read more…

The U.S. Food and Drug Administration (FDA) approved idecabtagene vicleucel (ide-cel) for the treatment of adults with relapsed/refractory multiple myeloma (RRMM) following four or more previous treatments, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody. Ide-cel is the first B-cell maturation antigen (BCMA)-targeted chimeric antigen receptor Read more…

The combination of pyrotinib plus capecitabine resulted in a statistically significant improvement in progression-free survival compared with lapatinib (Tykerb) plus capecitabine as treatment of patients with previously treated HER2-positive metastatic breast cancer, according to data published in The Lancet Oncology. The pyrotinib-plus-capecitabine combination also maintained a tolerable safety profile, presenting itself Read more…

Preliminary results of a phase 2 study suggest that the addition of the PI3K inhibitor copanlisib to chemotherapy in the first-line setting was not associated with survival benefit in patients with advanced CCA. While chemotherapy with gemcitabine and cisplatin remains the current standard of care as first-line therapy for patients with advanced Read more…

New research suggests that initiating aspirin use in older patients is not associated with a lower risk of colorectal cancer in these individuals.  Nevertheless, the pooled analysis of two cohort studies found that people who used aspirin before 70 years of age and continued into their 70s or later had a reduced Read more…

The monoclonal antibody pembrolizumab (Keytruda; Merck) provides statistically significant improvements in progression-free survival relative to standard chemotherapy as first-line treatment in patients with microsatellite-instability high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer, new research has concluded.  Read More…